INNV

InnovAge is the #1 PACE provider (~7,740 participants, 20 centers, six states) serving high-cost dual-eligible seniors under fully-capitated government contracts. The top line is genuinely healthy: revenue grew to $854M (+11.8% YoY) and has compounded from $638M in FY2021, while gross profit rose 16.3% — faster than revenue. The standout is cash: operating cash flow jumped to $32.9M (+189.1%) against just $6.26M of capex, so the business is now self-funding and free-cash-flow positive, and the balance sheet is sound — $64.1M cash roughly offsets ~$60M total debt, equity is $235M and liabilities/equity is a modest 1.12x. That cash generation is the single best reason not to be bearish here.

But the earnings quality is poor and getting worse, not better. The company has lost money every year for five years, and FY2025 losses re-accelerated: net income fell to -$30.3M (worse by 42.1% YoY), operating income was -$29.8M, net margin -3.6% and ROE -12.9%. The accumulated deficit deepened to -$101M. This is the structural flaw of a capitated model — InnovAge owns all the cost risk, and MD&A is explicit that cost of care per participant rose in FY2025 on wages/benefits, and that FY2026 will see *further* increases from OBBBA budget pressure, state Medicaid cuts to third-party providers, and persistent geriatric labor shortages. Management hopes 'clinical and operational value initiatives' offset this, but the forward operating picture as the company describes it is one of margin pressure, not relief.